Mesoblast Limited - ASX: MSB.......USOTC: MBLTY


Mesoblast is a world leader in developing innovative cellular medicines.

We have established what we believe is the industry’s most clinically advanced and diverse portfolio of cell-based products with three programs in active Phase 3 clinical studies.

Our lead product candidates under investigation are:

  • MPC-150-IM for chronic heart failure
  • MPC-06-ID for chronic low back pain due to disc degeneration
  • MSC-100-IV for acute graft versus host disease
  • MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy

We also have a strong emerging pipeline of products for follow-on indications.


505 Fifth Avenue, Level 3
New York, New York 10017
United States

Get Directions

Upgrade Your Listing